Search

Ying Chen,1,2,* Wen-Xia Li,1,2,* Jia-Hua Wu,1,2 Geng-Hang Chen,2 Chun-Min Yang,1,2 Hai Lu,1,2 Xi Wang,3 Shu-Sen Wang,4 Heng Huang,5 Li Cai,6 Li Zhao,7 Rou-Jun Peng,8 Ying Lin,9 Jun Tang,3 Jian Zeng,10 Le-Hong Zhang,11 Yong-Li Ke,12 Xian-Ming Wang,13 Xin-Mei Liu,14 An-Qin Zhang,15 Fei Xu,4 Xi-Wen Bi,4 Jia-Jia Huang,4 Ji-Bin Li,16 Dan-Mei Pang,17 Cong Xue,4 Yan-Xia Shi,4 Zhen-Yu He,18 Huan-Xin Lin,18 Xin An,4 Wen Xia,4 Ye Cao,16 Ying Guo,16 Ruo-Xi Hong,4 Kui-Kui Jiang,4 Yong-Yi Zhong,4 Ge Zhang,19 Piyawan Tienchaiananda,20 Masahiro Oikawa,21 Zhong-Yu Yuan,4 Qian-Jun Chen22,23 1Department of Breast Surgery, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, People’s Republic of China; 2Department of Breast Surgery, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 3Department of Breast Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China; 4Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China; 5Department of Breast Oncology, Lianjiang People’s Hospital, Lianjiang, People’s Republic of China; 6Department of Medical Oncology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, People’s Republic of China; 7Department of Breast Oncology, Guangzhou First People Hospital, Guangzhou, People’s Republic of China; 8Department of Integrated Therapy in Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China; 9Department of Breast Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China; 10Department of Breast Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China; 11Department of Breast Oncology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China; 12Department of Breast Oncology, General Hospital of PLA Guangzhou Military Area, Guangzhou, People’s Republic of China; 13Department of Breast Oncology, Shenzhen Second People’s Hospital, Shenzhen, People’s Republic of China; 14Department of Breast Oncology, Haikou People’s Hospital, Haikou, People’s Republic of China; 15Department of Breast Oncology, Maternal and Child Health Care Hospital of Guangdong Province, Guangzhou, People’s Republic of China; 16Department of Good Clinical Practice, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China; 17Department of Medical Oncology, Foshan First People’s Hospital, Foshan, People’s Republic of China; 18Department of Radiotherapy, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China; 19Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong; 20Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Rangsit University, Rajavithi Hospital, Bangkok, Thailand; 21The Department of Breast Surgery, New-wa-kai Oikawa Hospital, Fukuoka, Japan; 22State Key Laboratory of Traditional Chinese Medicine Syndrome/Departments of Gynecologic Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 23State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Qian-Jun Chen, 55N, Neihuanxi Road, Guangzhou, Guangdong, 510006, People’s Republic of China, Tel +86 1868883505, Email cqj55@163.com Zhong-Yu Yuan, 651 Dongfeng Road, Guangzhou, Guangdong, 510060, People’s Republic of China, Tel +86 13798027658, Email yuanzhy@sysucc.org.cnPurpose: Results from studies of extended capecitabine after the standard adjuvant chemotherapy in early stage triple-negative breast cancer (TNBC) were inconsistent, and only low-dose capecitabine from the SYSUCC-001 trial improved disease-free survival (DFS). Adjustment of the conventional adjuvant chemotherapy doses affect the prognosis and may affect the efficacy of subsequent treatments. This study investigated whether the survival benefit of the SYSUCC-001 trial was affected by dose adjustment of the standard adjuvant chemotherapy or not.Patients and Methods: We reviewed the adjuvant chemotherapy regimens before the extended capecitabine in the SYSUCC-001 trial. Patients were classified into “consistent” (standard acceptable dose) and “inconsistent” (doses lower than acceptable dose) dose based on the minimum acceptable dose range in the landmark clinical trials. Cox proportional hazards model was used to investigate the impact of dose on the survival outcomes.Results: All 434 patients in SYSUCC-001 trial were enrolled in this study. Most of patients administered the anthracycline-taxane regimen accounted for 88.94%. Among patients in the “inconsistent” dose, 60.8% and 47% received lower doses of anthracycline and taxane separately. In the observation group, the “inconsistent” dose of anthracycline and taxane did not affect DFS compared with the “consistent” dose. Moreover, in the capecitabine group, the “inconsistent” anthracycline dose did not affect DFS compared with the “consistent” dose. However, patients with “consistent” taxane doses benefited significantly from extended capecitabine (P=0.014). The sufficient dose of adjuvant taxane had a positive effect of extended capecitabine (hazard ratio [HR] 2.04; 95% confidence interval [CI] 1.02 to 4.06).Conclusion: This study found the dose reduction of adjuvant taxane might negatively impact the efficacy of capecitabine. Therefore, the reduction of anthracycline dose over paclitaxel should be given priority during conventional adjuvant chemotherapy, if patients need dose reduction and plan for extended capecitabine.Keywords: adjuvant chemotherapy, capecitabine, SYSUCC-001, triple-negative breast cancer, TNBC

Shi-Ping Yang,1,&ast; Ping Zhou,2,&ast; Chen-Lu Lian,2 Zhen-Yu He,3 San-Gang Wu2 1Department of Radiation Oncology, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, 570311, People’s Republic of China; 2Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, People’s Republic of China; 3Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Zhen-Yu He, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, 651 Dongfeng Road East, Guangzhou, 510060, People’s Republic of China, Tel +86 20 87343543, Fax +86 20 87343392, Email hezhy@sysucc.org.cn San-Gang Wu, Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, People’s Republic of China, Tel +86 592 2139531, Fax +86 592 2137222, Email unowu12345@hotmail.comBackground: The role of the 8th American Joint Committee on Cancer (AJCC) pathological prognostic staging (PPS) on treatment-decision making of breast cancer (BC) remains unclear. This study aimed to investigate the predictive effect of the 8th AJCC PPS on the benefit of postmastectomy radiotherapy (PMRT) in N2/N3 BC.Methods: We included women with stage N2/3 BC diagnosed between 2010 and 2018 from the Surveillance, Epidemiology, and End Results database. The effect of PMRT on breast cancer-specific survival (BCSS) was evaluated using the multivariate Cox proportional-hazards models.Results: A total of 13,445 patients were identified, including 10,547 (78.4%) patients treated with PMRT. All patients had reassigned stages based on the 8th AJCC PPS. There were 7102 patients (52.8%) that had stage changed, including 1160 patients (8.6%) were upstaged and 5942 patients (44.2%) were downstaged from the 7th AJCC anatomical staging (AS) to the 8th AJCC PPS. Regarding the 7th AJCC AS, 7603 (56.5%), 948 (7.1%), and 4895 (36.4%) were stage IIIA, IIIB, and IIIC diseases, respectively. Using the 8th AJCC PPS, 3525 (26.2%), 460 (3.4%), 1335 (9.9%), 3457 (25.7%), 2169 (19.1%), and 2100 (15.6%) patients were restaged as IB, IIA, IIB, IIIA, IIIB, and IIIC diseases, respectively. The PPS displayed increased prognostic accuracy and improved model fit with respect to BCSS compared to the 7th AS (C-index, 0.731 vs 0.605, P < 0.001; Akaike Information Criterion, 42141 vs 43118). Regarding the AS, the receipt of PMRT was associated with a better BCSS in those with stage IIIA (P = 0.004), IIIB (P = 0.003), and IIIC (P < 0.001) diseases. Using the PPS, the receipt of PMRT was not associated with a better BCSS among patients with stage IB (P = 0.446), IIA (P = 0.140), and IIB (P = 0.248) disease, while the receipt of PMRT was associated with a better BCSS for those with stage IIIA (P = 0.009), IIIB (P < 0.001), and IIIC (P < 0.001) disease.Conclusion: The 8th AJCC staging provides superior risk stratification and a better tool to predict the benefit of PMRT in N2/3 BC.Keywords: breast cancer, mastectomy, radiotherapy, AJCC staging, biologic markers

Li Dong,1 Yu-Min Zheng,2 Xiao-Guang Luo,3 Zhi-Yi He2 1Department of Neurology, The Fourth Affiliated Hospital of China Medical University, Shenyang, People’s Republic of China; 2Department of Neurology, The First Affiliated Hospital of China Medical University, Shenyang, People’s Republic of China; 3Department of Neurology, The First Affiliated Hospital of South University of Science and Technology, The Second Clinical College of Jinan University, Shenzhen People’s Hospital, Shenzhen, People’s Republic of ChinaCorrespondence: Xiao-Guang LuoDepartment of Neurology, The First Affiliated Hospital of South University of Science and Technology, The Second Clinical College of Jinan University, Shenzhen People’s Hospital, Shenzhen, People’s Republic of ChinaEmail guanche537@126.comZhi-Yi HeDepartment of Neurology, The First Affiliated Hospital of China Medical University, Shenyang, People’s Republic of ChinaEmail yizizhan40559@163.comBackground: Parkinson’s disease is a common neurodegenerative disease in the elderly. The incidence of various cancers in Parkinson’s disease patients is significantly lower than in healthy people. Parkinson’s disease patients are individuals with a high tendency for inflammation, whose peripheral immune system is represented in an activated state. We hypothesized that the hyperinflammatory predisposition of Parkinson’s disease patients is pathogenic.Methods: DBA/1 mice were used to simulate “highly inflammatory individuals”, and the carcinogen DEN was used to induce malignancy. Hematoxylin & eosin (H&E) staining was used to observe the formation of lung tumors. Apoptosis of neurons was observed by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining. Immunohistochemistry and flow cytometry were used to observe CD4, CD28, major histocompatibility complex II (MHCII), cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and programmed death 1 (PD-1). The ionized calcium binding adaptor molecule-1 (IBA-1) + inducible nitric oxide synthase (iNOS) was used to label M1 microglia, and IBA-1 + arginase 1 (Arg1) was used to label M2 microglia by immunofluorescence. The expression of pro-inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and anti-inflammatory cytokines IL-10 and IL-4 was detected by ELISA.Results: DBA/1 mice with high inflammatory tendency showed a continuous increase of peripheral inflammation, promoting intracranial inflammation, decreasing the tumor incidence and increasing the neurodegeneration under induction of malignant change. CD28 and CTLA-4/PD-1 reduced the T-cell-dominated inflammatory response, reduced the intracerebral inflammatory response, protected from neurodegeneration, and increased the incidence of tumor. Combination of CTLA-4 and PD-1 blocker can overactivate T cells, worsen peripheral and intracranial inflammation, reduce the incidence of tumor, cause damage to dopamine neurons, and promote the occurrence of neurodegeneration.Conclusion: High inflammatory tendency induced by malignant stimulation through the imbalance of CD28 and CTLA-4/PD-1 leads to dopamine neuron injury.Keywords: high inflammatory tendency, malignant stimulation, CD28, CTLA-4/PD-1, dopamine neuron injury

Zhi-Qing Long,1,* Xin Hua,1,* Wen-Wen Zhang,1 Shao-Wen Lv,1 Jia-Peng Deng,1 Ling Guo,2 Zhen-Yu He,1 Huan-Xin Lin11Department of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China; 2Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China*These authors contributed equally to this workIntroduction: Albumin and alkaline phosphatase have been previously demonstrated as independent prognostic factors for various types of cancer. Here, we aimed to explore the potential value of pretreatment albumin to alkaline phosphatase ratio (AAPR) on overall survival (OS) in nonmetastatic breast cancer patients.Methods: A total of 746 nonmetastatic breast cancer patients were enrolled in this study. Receiver characteristic curve was used to analyze the AAPR threshold. Survival analysis was conducted using the Kaplan–Meier method and compared with the log-rank test. Both univariate and multivariate analyses were performed using Cox proportional hazards regression methodology.Results: The optimal cutoff value of AAPR in predicting OS in nonmetastatic breast cancer patients was 0.525. Increased pretreatment AAPR level was related to age at diagnosis (≥60 years vs 2 cm, P=0.034), estrogen receptor (positive vs negative, P=0.022), progesterone receptor (positive vs negative, P=0.025), carcino-embryonic antigen (abnormal vs normal, P=0.016), surgery (lumpectomy vs mastectomy, P=0.002), chemotherapy (yes vs no, P=0.004), radiotherapy (yes vs no, P=0.013), endocrine therapy (yes vs no, P=0.027) but not with lymph node involvement, HER-2 status or CA-153. The 5-year OS rate was 80.16% for the low AAPR group and 92.66% for the high AAPR group. Kaplan–Meier analysis indicated that patients with low-AAPR levels had shorter OS than patients with high-AAPR levels (P=0.001). N classification (P

Zhi-Yong He,1,2,* Mei-Fang Li,1,2,* Jing-Hui Lin,1,2 Dong Lin,1,2 Ren-Jang Lin3 1Department of Thoracic Medical Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, Fujian Province, People’s Republic of China; 2Fujian Provincial Key Laboratory of Translation Cancer Medicine, Fuzhou 350014, Fujian Province, People’s Republic of China; 3Department of Molecular and Cellular Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA *These authors contributed equally to this work Background: Non-small-cell lung cancer (NSCLC) is a global public health problem, and brain is a common metastatic site in advanced NSCLC. Currently, whole-brain radiotherapy (WBRT) remains a major treatment for brain metastases, while EGFR-tyrosine kinase inhibitor (TKI) is the standard treatment for advanced NSCLC harboring EGFR mutations, which is also effective for brain metastases. However, whether EGFR-TKIs plus radiotherapy is superior to EGFR-TKIs alone for the treatment of advanced EGFR-mutant NSCLS with brain metastases remains controversial. This study aimed to compare the efficacy of concurrent EGFR-TKIs and WBRT vs EGFR-TKI alone in a retrospective cohort of advanced EGFR-mutant NSCLS with brain metastases.Patients and methods: The medical records of 104 treatment-naïve, advanced EGFR-mutant NSCLC patients with brain metastases were retrospectively reviewed, and there were 56 patients undergoing concurrent EGFR-TKI and WBRT, and 48 patients given EGFR-TKI alone, including 20 cases with salvage WBRT upon brain metastasis progression. The survival prognosis was compared between the two cohorts.Results: The baseline clinicopathologic factors were balanced between the two cohorts. After a median follow-up of 23 months, 35.6% of the study subjects survived. Concurrent EGFR-TKI and WBRT significantly improved the median intracranial PFS (iPFS) compared with EGFR-TKI alone (17.7 vs 11.0 months, P=0.015); however, no significant difference was seen in median overall survival between the two cohorts (28.1 vs 24.0 months, P=0.756). In addition, the median iPFS was found to significantly vary in the number of brain metastases (≤3 vs>3 metastases: 18.0 vs 12.5 months, P=0.044). Subgroup analysis showed that concurrent EGFR-TKI and WBRT improved median iPFS compared with EGFR-TKI alone in patients with more than three brain metastases (P=0.001); however, no significant difference was observed between the two regimens in patients with three or less brain metastases (P=0.526).Conclusion: Our data demonstrate that concurrent EGFR-TKI and WBRT achieves longer iPFS than EGFR-TKI alone in advanced EGFR-mutant NSCLC with brain metastases. In advanced EGFR-mutant NSCLC with three or less brain metastases, EGFR-TKI alone may be an option as a first-line therapy. Keywords: non-small-cell lung cancer, brain metastasis, epidermal growth factor receptor, tyrosine kinase inhibitor, whole-brain radiotherapy

Wen-Wen Zhang,1,* San-Gang Wu,2,* Yi-Hong Ling,3 Jia-Yuan Sun,1 Zhi-Qing Long,1 Xin Hua,1 Yong Dong,4 Feng-Yan Li,1 Zhen-Yu He,1 Huan-Xin Lin1 1Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China; 2Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, People’s Republic of China; 3Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China; 4Department of Radiation Oncology, the Third People’s Hospital of Dongguan, Dongguan, Guangdong, People’s Republic of China *These authors contributed equally to this work Introduction: We aimed to evaluate the clinicopathologic characteristics and clinical outcomes of the mixed type versus the pure type of tubular carcinoma (TC) of the breast in a retrospective cohort study. Materials and methods: Patients were categorized into the following three groups: patients with pure TC of the breast (the PTC group), patients with TC and carcinoma in situ of the breast (the TC-CIS group), and patients with TC and other invasive carcinomas of the breast (the TC-IC group). We compared the clinicopathologic characteristics and treatment outcomes of the three groups. The primary end point of this study was breast cancer-specific survival (BCSS). Secondary end points included distant metastasis-free survival (DMFS) and locoregional recurrence (LRR). Results: A total of 68 patients were included in this study, including 31 patients in the PTC group, 12 in the TC-CIS group, and 25 in the TC-IC group. Our data showed that PTC and TC-CIS were more likely to be smaller in size (P=0.014) and had substantially less nodal involvement (P=0.019), compared with TC-IC. The median follow-up time was 64.3 months (range, 3.78–223.2 months) for all patients. No locoregional relapse was observed in any group during the follow-up period. The 10-year BCSS of the PTC, TC-CIS, and TC-IC groups was 100%, 100%, and 95.2%, respectively, and the 10-year DMFS was 92.3%, 100%, and 96.0%, respectively. There was no significant difference in terms of BCSS (P=0.53) or DMFS (P=0.84) between the three groups. Conclusion: This study indicates that both the pure type and mixed type of TC of the breast show very low LRR and distant metastasis rate and have excellent survival. The TC-IC group is likely to show good prognosis similar to the PTC group. Further clinical trials with larger sample sizes as well as molecular and genetic studies are warranted. Keywords: pure type of tubular carcinoma, mixed type of tubular carcinoma, clinicopathologic characteristics, clinical outcomes

Wen-Wen Zhang,1,* San-Gang Wu,2,* Jia-Yuan Sun,1 Feng-Yan Li,1 Zhen-Yu He1 1Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, People’s Republic of China; 2Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen 361003, People’s Republic of China *These authors contributed equally to this work Introduction: The timing of postmastectomy radiotherapy (PMRT) may influence locoregional recurrence and survival outcomes. In this study, we assessed the long-term survival effect of the interval between surgery and PMRT in locally advanced breast cancer treated with mastectomy and adjuvant chemotherapy.Methods: In this retrospective study, we included women with locally advanced breast cancer who underwent adjuvant chemotherapy and PMRT after mastectomy between 1999 and 2007. Based on the interval between surgery and PMRT, the patients were classified into three groups: Group 1 (≤4 vs >4 months), Group 2 (≤5 vs >5 months), and Group 3 (≤6 vs >6 months). Univariate and multivariate regression analyses were performed to determine the prognostic factors of survival outcomes.Results: A total of 340 women were included in this study, and the median follow-up duration was 79.8 months. The median surgery–PMRT interval was 5 months. The surgery–PMRT interval including Group 1, Group 2, and Group 3 was not significantly associated with locoregional recurrence-free survival, distant metastasis-free survival, disease-free survival, and overall survival. In addition, in the subgroup analysis of the effect of surgery–PMRT interval on survival outcomes according to various clinicopathologic factors, the surgery–PMRT interval was also not associated with survival outcomes in different age groups, tumor stage, and breast cancer subtypes.Conclusion: Our findings suggest that the delay in the start of PMRT in locally advanced breast cancer does not increase the likelihood of locoregional recurrence, distant metastasis, and death. Keywords: breast carcinoma, surgery, time, irradiation, delay

San-Gang Wu,1,* Wen-Wen Zhang,2,* Jia-Yuan Sun,2 Qin Lin,1 Zhen-Yu He2 1Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen 361003, People’s Republic of China; 2Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, People’s Republic of China *These authors contributed equally to this work Objective: To compare the survival outcomes in locally advanced breast cancer (LABC) patients receiving post-mastectomy radiotherapy (PMRT) with and without immediate breast reconstruction. Methods: We used the Surveillance, Epidemiology, and End Results program to include LABC patients who were treated/not treated with immediate breast reconstruction followed by PMRT between 2003 and 2010. Statistical analysis was performed using the chi-squared test, Kaplan–Meier survival analysis, and Cox regression analysis. A 1:1 propensity score matching method was performed to decrease the selection bias. Results: We identified 1,732 patient-pairs that were completely matched. In the unmatched population, 8,198 and 1,802 patients received mastectomy only and immediate breast reconstruction, respectively. Patients who received immediate breast reconstruction had better breast cancer-specific survival (BCSS) (hazard ratio [HR] 0.880, 95% CI 0.783–0.989, P = 0.032) and overall survival (OS) (HR 0.846, 95% CI 0.758–0.943, P = 0.003) than patients who underwent mastectomy alone. However, in the matched population, there was comparable BCSS and OS between patients who received immediate breast reconstruction and mastectomy alone. Subset analysis in the matched population found that immediate breast reconstruction was associated with better BCSS (HR 0.750, 95% CI 0.614–0.917, P = 0.005) and OS (HR 0.779, 95% CI 0.644–0.942, P = 0.010) compared to patients aged

San-Gang Wu,1,* Wen-Wen Zhang,2,* Jia-Yuan Sun,2 Zhen-Yu He2 1Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, People’s Republic of China; 2Department of Radiation Oncology, Sun Yat-sen University Cancer Center, and State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, People’s Republic of China *These authors contributed equally to this work Background: The prognostic implication of concomitant ductal carcinoma in situ (DCIS) in invasive ductal carcinoma (IDC) remains controversial. Our objective was to investigate whether concomitant DCIS affects survival outcomes in patients with IDC.Materials and methods: Patients with nonmetastatic breast cancer who underwent surgery in 2010–2014 were included from the Surveillance, Epidemiology, and End Results program. Statistical analyses were conducted using Χ2 test, linear-by-linear association, one-way analysis of variance, Kaplan–Meier method, Cox proportional hazards regression model, and propensity score matching (PSM).Results: A total of 61,745 patients were identified, including 44,630 (72.3%), 13,559 (22.0%), and 3,556 (5.7%) patients with no DCIS component reported (No-DCIS), DCIS

Juan Zhou,1,* Wen-Wen Zhang,2,* Fang Peng,3 Jia-Yuan Sun,2 Zhen-Yu He,2 San-Gang Wu4 1Department of Obstetrics and Gynecology, the First Affiliated Hospital of Xiamen University, Xiamen 361003, People’s Republic of China; 2Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, People’s Republic of China; 3Department of Radiation Oncology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, People’s Republic of China; 4Department of Radiation Oncology, Xiamen Cancer Hospital, the First Affiliated Hospital of Xiamen University, Xiamen 361003, People’s Republic of China *These authors contributed equally to this work Introduction: Although some circRNAs have been found to regulate the progression of malignancies, their functions and coupled molecular mechanisms are still unclear. In our study, we sought to assess the underlying molecular mechanisms of circRNAs in breast cancer and therefore explored the differentially expressed circRNAs and co-expression networks, followed by in vitro experiments. Materials and methods: High-throughput RNA sequencing was performed to obtain an unbiased profile of circRNA expression. CircRNA-miRNA-mRNA co-expression networks were predicted, and sequence analyses were carried out. The MTT, transwell migration and invasion assay was conducted in Michigan Cancer Foundation-7 cells that had been transfected with si-circRNA and si-negative control (si-NC). Results: A total of 152 circRNAs were differentially expressed in breast cancer tissues, among which 85 were upregulated and 67 downregulated. Out of these, hsa_circ_0011946 was selected and the subsequent bioinformatics analysis predicted that hsa_circ_0011946 sponging miR-26a/b directly targeted replication factor C subunit 3 (RFC3) and that its knockdown could inhibit RFC3 mRNA and protein expression. Furthermore, hsa_circ_0011946 loss-of-function significantly suppressed the migration and invasion of Michigan Cancer Foundation-7 cells. Conclusion: Together, these results indicate that hsa_circ_0011946 and RFC3 comprise a novel pathway involved in the progression of breast cancer. Keywords: hsa_circ_0011946, MCF-7, RFC, breast cancer, high-throughput sequencing

San-Gang Wu,1,* Wen-Wen Zhang,2,* Zhen-Yu He,2 Jia-Yuan Sun,2 Yan Wang,3 Juan Zhou3 1Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, People’s Republic of China; 2Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, People’s Republic of China; 3Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xiamen University, Xiamen, People’s Republic of China *These authors contributed equally to this work Introduction: There is an ongoing debate regarding the optimal local treatment modalities for stage IB1 and IIA1 cervical cancer. The aim of this study was to determine whether radical hysterectomy or definitive radiochemotherapy is superior in stage IB1 and IIA1 cervical squamous cell carcinoma (SCC).Methods: From 1990 to 2010, a total of 3,769 patients with stage IB1 and IIA1 cervical SCC were included from the Surveillance, Epidemiology, and End Results database and were stratified according to whether they received radical hysterectomy or primary radiochemotherapy. Propensity score-matching (PSM) methods were used to balance patient baseline characteristics. Cancer-specific survival (CSS) and overall survival (OS) were compared between the two groups.Results: Of the 3,769 patients, 3,653 (96.9%) and 116 (3.1%) patients received radical hysterectomy and definitive radiochemotherapy, respectively. Radiochemotherapy was rarely used for definitive treatment prior to 2000. Before PSM, patients who were older, of black ethnicity, and with larger tumor size and stage IIA1 disease were more likely to receive definitive radiochemotherapy. A total of 116 pairs were completely matched using PSM. The local treatment modalities had no effect on CSS or OS in either unmatched or matched populations. In the matched population, the 8-year CSS rates were 82.1% and 76.5% in surgery and radiochemotherapy groups, respectively (p=0.382). The 8-year OS rates were 74.6% and 67.8% in surgery and radiochemotherapy groups, respectively (p=0.205).Conclusion: Our population-based study suggests that there is no clear local treatment of choice on survival outcomes between radical hysterectomy and definitive radiochemotherapy in patients with stage IB1 and IIA1 cervical SCC. Keywords: cervical cancer, early stage, hysterectomy, radiotherapy, propensity score matching

San-Gang Wu,1,* Wen-Wen Zhang,2,* Zhen-Yu He,2 Jia-Yuan Sun,2 Yong-Xiong Chen,3 Ling Guo4 1Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, 2Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 3Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Medical College, Xiamen University, Xiamen, 4Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, People’s Republic of China *These authors contributed equally to this work. Background: There are few population-based studies of the sites of distant metastasis (DM) and survival from esophageal cancer (EC). The aim of this study was to assess the patterns and survival outcomes for site-specific DM from EC using a population-based approach.Methods: Patients diagnosed with de novo stage IV EC between 2010 and 2014 were identified from the Surveillance, Epidemiology, and End Results program database. Overall survival (OS) was compared according to the site of DM.Results: We included 3218 patients in this study; the most common site of DM was the liver, followed by distant lymph nodes, lung, bone and brain. Median OS for patients with liver, distant lymph node, lung, bone, and brain metastases was 5, 10, 6, 4, and 6 months, respectively (p

San-Gang Wu,1,* Wen-Wen Zhang,2,* Jia-Yuan Sun,2 Feng-Yan Li,2 Yong-Xiong Chen,3 Zhen-Yu He2 1Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, 2Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 3Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Medical College, Xiamen University, Xiamen, People’s Republic of China *These authors contributed equally to this work Introduction: Invasive micropapillary carcinoma (IMPC) of the breast poses a high risk of locoregional recurrence, and postoperative radiotherapy (PORT) may be beneficial in IMPC. Hence, we determined the clinical value of PORT in IMPC patients. Patients and methods: We assessed clinicopathological factors extracted from the Surveillance, Epidemiology, and End Results database (2004–2013). Univariate and multivariate Cox proportional hazards regressions were performed to assess the independent prognostic factors on breast cancer-specific survival (BCSS) and overall survival (OS). Results: Of the 881 study patients, 444 (50.4%) and 437 (49.6%) underwent breast-conserving surgery (BCS) and mastectomy (MAST), respectively, of whom 357 (80.4%) and 153 (35.0%) underwent PORT, respectively. Patients with young age, large tumor size, or advanced nodal stage were more likely to undergo MAST and PORT compared with MAST alone. Patients with progesterone receptor-positive disease were more likely to receive BCS and PORT compared with BCS alone. The 5-year BCSS and OS were 95.7% and 90.9%, respectively. On multivariate analyses, tumor size, histological grade, and estrogen receptor status were independent predictors of BCSS and OS. The types of surgical procedures (MAST vs. BCS) were not an independent predictor of survival outcomes. Patients who underwent MAST with or without PORT had similar BCSS and OS in the multivariate analyses. Those who underwent BCS plus PORT did not have better BCSS and OS than those who underwent BCS alone. In the low-, intermediate-, and high-risk groups, PORT was not associated with better BCSS and OS than non-PORT groups in patients who received BCS or MAST. Conclusion: IMPC has favorable BCSS and OS. Regardless of the types of surgical procedures (MAST or BCS), PORT groups were not inferior to non-PORT groups on BCSS and OS. Keywords: invasive micropapillary carcinoma, SEER, radiotherapy, survival

Juan Zhou,1,* Wen-Wen Zhang,2,* San-Gang Wu,3 Zhen-Yu He,2 Jia-Yuan Sun,2 Yan Wang,4 Qiong-Hua Chen1 1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xiamen University, Xiamen, 2Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 3Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, 4Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People’s Republic of China *These authors contributed equally to this work. Introduction: The prognostic impact of the number of examined lymph nodes (ELNs) in different histological subtypes of cervical cancer remains unclear. We aimed to assess the impact of the number of ELNs in stage IA2–IIA cervical cancer with different histological subtypes. Methods: Data of patients with stage IA2–IIA squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the uterine cervix between 1988 and 2013 were retrieved from the Surveillance, Epidemiology, and End Results program. Univariate and multivariate Cox regression analyses were performed to analyze the effect of number of ELNs on cause-specific survival (CSS) and overall survival (OS). Results: The final data set identified 11,830 patients including 7,920 (66.9%) women with SCC and 3,910 (33.1%) with AC. The median number of ELNs was 19. The multivariate analysis indicated that the number of ELNs was an independent prognostic factor influencing CSS and OS, both as a continuous or a categorical variable. Patients with a higher number of ELNs had better survival outcomes. In SCC subtype, the number of ELNs was also the independent prognostic factor of CSS and OS in node-positive patients, but not in patients with node-negative disease. In AC patients, ELN count was not an independent predictor of CSS and OS regardless of lymph node status. Conclusion: The number of ELNs is an independent prognostic factor in patients with stage IA2–IIB cervical cancer. A higher number of ELNs is associated with better survival outcomes, especially in the node-positive SCC subtype. Keywords: cervical cancer, early stage, SEER, histological subtype, nodal positive, prognosis

Su-Ping Guo,1,* San-Gang Wu,2,* Juan Zhou,3,* Hui-Xia Feng,1 Feng-Yan Li,1 Ying-Jia Wu,1 Jia-Yuan Sun,1 Zhen-Yu He1 1Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China; 2Department of Radiation Oncology, Xiamen Cancer Center, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China; 3Department of Obstetrics and Gynecology, Xiamen Cancer Center, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China *These authors contributed equally to this work Abstract: This study evaluated the efficacy, safety, and quality of life (QoL) measure of transdermal fentanyl (TDF) for moderate-to-severe pain due to oral mucositis caused by chemoradiotherapy in patients with advanced nasopharyngeal carcinoma (NPC). Patients with NPC who experienced moderate-to-severe oral mucosal pain during chemoradiotherapy (n=78) received TDF for pain relief. Pain relief and QoL were compared before and after treatment. The mean numeric rating scale score was reduced from 7.41±0.96 before treatment to 5.54±0.86, 3.27±0.73, 2.88±0.62, and 2.82±0.68 on days 1, 4, 7, and 10, respectively, after treatment (P

We study $D_{s}^{+}$ decays to final states involving the $\eta'$ with a482$\,$pb$^{-1}$ data sample collected at $\sqrt{s}$ = 4.009$\,$GeV with the\mbox{BESIII} detector at the BEPCII collider. We measure the branchingfractions $\mathcal{B}(D^+_{s}\rightarrow \eta'X)$ = (8.8$\pm$1.8$\pm$0.5)$\%$and $\mathcal{B}(D_{s}^{+}\rightarrow \eta'\rho^{+})$ = ($5.8\pm1.4\pm0.4$)$\%$where the first uncertainty is statistical and the second is systematic. Inaddition, we estimate an upper limit on the non-resonant branching ratio$\mathcal{B}(D_{s}^{+}\rightarrow \eta'\pi^+\pi^0)

We study $D_{s}^{+}$ decays to final states involving the $\eta'$ with a482$\,$pb$^{-1}$ data sample collected at $\sqrt{s}$ = 4.009$\,$GeV with the\mbox{BESIII} detector at the BEPCII collider. We measure the branchingfractions $\mathcal{B}(D^+_{s}\rightarrow \eta'X)$ = (8.8$\pm$1.8$\pm$0.5)$\%$and $\mathcal{B}(D_{s}^{+}\rightarrow \eta'\rho^{+})$ = ($5.8\pm1.4\pm0.4$)$\%$where the first uncertainty is statistical and the second is systematic. Inaddition, we estimate an upper limit on the non-resonant branching ratio$\mathcal{B}(D_{s}^{+}\rightarrow \eta'\pi^+\pi^0)

We report a study of the process e^{+}e^{-}→(D^{*}D[over ¯]^{*})^{0}π^{0} using e^{+}e^{-} collision data samples with integrated luminosities of 1092 pb^{-1} at sqrt[s]=4.23 GeV and 826 pb^{-1} at sqrt[s]=4.26 GeV collected with the BESIII detector at the BEPCII storage ring. We observe a new neutral structure near the (D^{*}D[over ¯]^{*})^{0} mass threshold in the π^{0} recoil mass spectrum, which we denote as Z_{c}(4025)^{0}. Assuming a Breit-Wigner line shape, its pole mass and pole width are determined to be (4025.5_{-4.7}^{+2.0}±3.1) MeV/c^{2} and (23.0±6.0±1.0) MeV, respectively. The Born cross sections of e^{+}e^{-}→Z_{c}(4025)^{0}π^{0}→(D^{*}D[over ¯]^{*})^{0}π^{0} are measured to be (61.6±8.2±9.0) pb at sqrt[s]=4.23 GeV and (43.4±8.0±5.4) pb at sqrt[s]=4.26 GeV. The first uncertainties are statistical and the second are systematic.

Using the data sets taken at center-of-mass energies above 4 GeV by the BESIII detector at the BEPCII storage ring, we search for the reaction e+e-→γISRX(3872)→γISRπ+π-J/ψ via the Initial State Radiation technique. The production of a resonance with quantum numbers JPC=1++ such as the X(3872) via single photon e+e- annihilation is forbidden, but is allowed by a next-to-leading order box diagram. We do not observe a significant signal of X(3872), and therefore give an upper limit for the electronic width times the branching fraction ΓeeX(3872)B(X(3872)→π+π-J/ψ)

From December 2011 to May 2014, about 5 fb-1 of data were taken with the BESIII detector at center-of-mass energies between 3.810 GeV and 4.600 GeV to study the charmonium-like states and higher excited charmonium states. The time-integrated luminosity of the collected data sample is measured to a precision of 1% by analyzing events produced by the large-angle Bhabha scattering process.

We report an observation of the process J/ψ→γX(1835)→γK_{S}^{0}K_{S}^{0}η at low K_{S}^{0}K_{S}^{0} mass with a statistical significance larger than 12.9σ using a data sample of 1.31×10^{9} J/ψ events collected with the BESIII detector. In this region of phase space the K_{S}^{0}K_{S}^{0} system is dominantly produced through the f_{0}(980). By performing a partial wave analysis, we determine the spin parity of the X(1835) to be J^{PC}=0^{-+}. The mass and width of the observed X(1835) are 1844±9(stat)_{-25}^{+16}(syst)  MeV/c^{2} and 192_{-17}^{+20}(stat)_{-43}^{+62}(syst)  MeV, respectively, which are consistent with the results obtained by BESIII in the channel J/ψ→γπ^{+}π^{-}η^{'}.

We report the observation of the X(3823) state in the process e+e-→π+π-X(3823)→π+π-γχc1 with a statistical significance of 6.2σ, in data samples at center-of-mass energies sqrt[s]=4.230, 4.260, 4.360, 4.420, and 4.600 GeV collected with the BESIII detector at the BEPCII electron positron collider. The measured mass of the X(3823) state is (3821.7±1.3±0.7)  MeV/c2, where the first error is statistical and the second systematic, and the width is less than 16 MeV at the 90% confidence level. The products of the Born cross sections for e+e-→π+π-X(3823) and the branching ratio B[X(3823)→γχc1,c2] are also measured. These measurements are in good agreement with the assignment of the X(3823) state as the ψ(1 3D2) charmonium state.

Using data samples collected at center-of-mass energies of √s= 4.009, 4.226, 4.257, 4.358, 4.416, and 4.599 GeV with the BESIII detector operating at the BEPCII storage ring, we search for the isospin violating decay Y(4260) → J/ψηπ0. No signal is observed, and upper limits on the cross section σ(e+e− → J/ψηπ0) at the 90% confidence level are determined to be 3.6, 1.7, 2.4, 1.4, 0.9, and 1.9 pb, respectively.

We report the first observation of the Dalitz decay η’→γe+e−, based on a data sample of 1.31 billion J/ψ events collected with the BESIII detector. The η’ mesons are produced via the J/ψ→γη’ decay process. The ratio Γ(η’→γe+e−)/Γ(η’→γγ) is measured to be (2.13±0.09(stat)±0.07(sys))×10−2. This corresponds to a branching fraction B(η’→γe+e−)=(4.69±0.20(stat)±0.23(sys))×10−4. The transition form factor is extracted and different expressions are compared to the measured dependence on the e+e− invariant mass. The results are consistent with the prediction of the vector meson dominance model.

Using a sample of 1.31×109 J/ψ events collected with the BESIII detector at the BEPCII collider, the decays J/ψ→φπ+π-π0 and J/ψ→φπ0π0π0 are investigated. The isospin-violating decay J/ψ→φπ0f0(980) with f0(980)→ππ is observed for the first time. The width of the f0(980) obtained from the dipion mass spectrum is found to be much smaller than the world average value. In the π0f0(980) mass spectrum, there is evidence of f1(1285) production. By studying the decay J/ψ→φη′, the branching fractions of η′→π+π-π0 and η′→π0π0π0, as well as their ratio, are also measured.

Based on a sample of 1.31×109 J/ψ events collected with the BESIII detector at the BEPCII collider, Dalitz plot analyses of selected 79,625 η→π+π-π0 events, 33,908 η→π0π0π0 events, and 1,888 η′→π0π0π0 events are performed. The measured matrix elements of η→π+π-π0 are in reasonable agreement with previous measurements. The Dalitz plot slope parameters of η→π0π0π0 and η′→π0π0π0 are determined to be -0.055±0.014±0.004 and -0.640±0.046±0.047, respectively, where the first uncertainties are statistical and the second systematic. Both values are consistent with previous measurements, while the precision of the latter one is improved by a factor of 3. Final state interactions are found to have an important role in those decays.

We present the first upper-limit measurement of the branching fractions of the isospin-violating transitions χc0,2 → π0ηc. The measurements are performed using 106×106ψ(3686) events accumulated with the BESIII detector at the BEPCII e+e- collider at a center-of-mass energy corresponding to the ψ(3686) mass. We obtained upper limits on the branching fractions at a 90% confidence level of B(χc0→ π0ηc)

Using a sample of 1.31 billion J/ψ events accumulated with the BESIII detector at the BEPCII collider, we report the observation of the decay J/ψ→φπ0, which is the first evidence for a doubly Okubo-Zweig-Iizuka suppressed electromagnetic J/ψ decay. A clear structure is observed in the K+K- mass spectrum around 1.02 GeV/c2, which can be attributed to interference between J/ψ→φπ0 and J/ψ→K+K-π0 decays. Due to this interference, two possible solutions are found. The corresponding measured values of the branching fraction of J/ψ→φπ0 are [2.94±0.16(stat)±0.16(syst)]×10-6 and [1.24±0.33(stat)±0.30(syst)]×10-7.

Using 2.92 fb-1 of electron-positron annihilation data collected at √s = 3.773 GeV with the BESIII detector, we report the results of a search for the flavor-changing neutral current process D0 →γγ using a double-tag technique. We find no signal and set an upper limit at 90% confidence level for the branching fraction of B(D0 →γγ)< 3.8 × 10-6. We also investigate D0-meson decay into two neutral pions, obtaining a branching fraction of B(D0 →π0π0)= (8.24 ± 0.21(stat) ± 0.30(syst)) × 10-4, the most precise measurement to date and consistent with the current world average.

Using a sample of 1.06×108ψ(3686) events produced in e+e- collisions at s=3.686 GeV and collected with the BESIII detector at the BEPCII collider, we present studies of the decays ψ(3686)→K-ΛΞ¯++c.c. and ψ(3686)→γK-ΛΞ¯++c.c.. We observe two hyperons, Ξ(1690)- and Ξ(1820)-, in the K-Λ invariant mass distribution in the decay ψ(3686)→K-ΛΞ¯++c.c. with significances of 4.9σ and 6.2σ, respectively. The branching fractions of ψ(3686)→K-ΛΞ¯++c.c., ψ(3686)→K-Σ0Ξ¯++c.c., ψ(3686)→γχcJ→γK-ΛΞ¯++c.c. (J=0, 1, 2), and ψ(3686)→Ξ(1690/1820)-Ξ¯++c.c. with subsequent decay Ξ(1690/1820)-→K-Λ are measured for the first time.

We report a measurement of the parameter yCP in D0-D-0 oscillations performed by taking advantage of quantum coherence between pairs of D0D-0 mesons produced in e+e- annihilations near threshold. In this work, doubly-tagged D0D-0 events, where one D decays to a CP eigenstate and the other D decays in a semileptonic mode, are reconstructed using a data sample of 2.92 fb-1 collected with the BESIII detector at the center-of-mass energy of s=3.773 GeV. We obtain yCP=(-2.0±1.3±0.7)%, where the first uncertainty is statistical and the second is systematic. This result is compatible with the current world average.

We report a measurement of the branching fraction for ψ(3770)→γχc1 and search for the transition ψ(3770)→γχc2 based on 2.92 fb-1 of e+e- data accumulated at s=3.773 GeV with the BESIII detector at the BEPCII collider. We measure B(ψ(3770)→γχc1)=(2.48±0.15±0.23)×10-3, which is the most precise measurement to date. The upper limit on the branching fraction of ψ(3770)→γχc2 at a 90% confidence level is B(ψ(3770)→γχc2)

Using data samples collected at center-of-mass energies of s = 4.009, 4.230, 4.260, and 4.360 GeV with the BESIII detector operating at the BEPCII collider, we perform a search for the process e+e- → γχcJ (J=0, 1, 2) and find evidence for e+e- → γχc1 and e+e- → γχc2 with statistical significances of 3.0σ and 3.4σ, respectively. The Born cross sections σB(e+e- → γχcJ), as well as their upper limits at the 90% confidence level (C.L.) are determined at each center-of-mass energy.

Based on data samples collected with the BESIII detector at the BEPCII collider at nine center of mass energies from 4.21 to 4.42 GeV, we search for the production of e^{+}e^{-}→ωχ_{cJ} (J=0, 1, 2). The process e^{+}e^{-}→ωχ_{c0} is observed for the first time, and the Born cross sections at sqrt[s]=4.23 and 4.26 GeV are measured to be (55.4±6.0±5.9) and (23.7±5.3±3.5)  pb, respectively, where the first uncertainties are statistical and the second are systematic. The ωχ_{c0} signals at the other seven energies and the e^{+}e^{-}→ωχ_{c1} and ωχ_{c2} signals are not significant, and the upper limits on the cross sections are determined. By examining the ωχ_{c0} cross section as a function of center of mass energy, we find that it is inconsistent with the line shape of the Y(4260) observed in e^{+}e^{-}→π^{+}π^{-}J/ψ. Assuming the ωχ_{c0} signals come from a single resonance, we extract the mass and width of the resonance to be (4230±8±6)  MeV/c^{2} and (38±12±2)  MeV, respectively, and the statistical significance is more than 9σ.

Using a sample of 2.25 × 108 J/ψ events collected with the BESIII detector at the BEPCII collider, we search for the J/ψ semileptonic weak decay J/ψ → D-s e+νe+ c.c. with a much higher sensitivity than previous searches. We also perform the first search for J/ψ → D∗-s e+νe + c.c. No significant excess of a signal above background is observed in either channel. At the 90% confidence level, the upper limits are determined to be B(J/ψ → D-s e+νe + c.c. )< 1.3 × 10-6 and B(J=ψ → D∗-s e+νe + c.c. ) < 1.8 × 10-6, respectively. Both are consistent with Standard Model predictions.

Using 1.06 × 108ψ (3686) events recorded in e+e-, collisions at √s = 3.686 GeV with the BESIII at the BEPCII collider, we present searches for C-parity violation in J/ψ → γγ and γφ decays via ψ(3686) → J/ψπ+π-. No significant signals are observed in either channel. Upper limits on the branching fractions are set to be B(J/ψ → γγ) < 2.7 × 10-7, and B(J/ψ → γφ>) < 1.4 × 10-6, at the 90% confidence level. The former is one order of magnitude more stringent than the previous upper limit, and the latter represents the first limit on this decay channel.

Using 2.25 × 108, J/ψ events collected with the BESIII detector at the BEPCII storage rings, we observe for the first time the process J/ψ → pp¯a0(980), a0(980) → π0η with a significance of 6.5σ (3.2σ including systematic uncertainties). The product branching fraction of J/ψ → pp¯a0 (980) → pp¯ π0η is measured to be (6.8 ± 1.2 ± 1.3) × 10-5, where the first error is statistical and the second is systematic. This measurement provides information on the a0 production near threshold coupling to pp and improves the understanding of the dynamics of J/ψ decays to four-body processes.

The process e+e−→ pp̄π0has been studied by analyzing data collected at (formula presented) GeV, at (formula presented) GeV, and during a ψ(3770) line shape scan with the BESIII detector at the BEPCII collider. The Born cross section of p̄pπ0in the vicinity of the ψ(3770) is measured, and the Born cross section of ψ(3770) → p̄pπ0is extracted considering interference between resonant and continuum production amplitudes. Two solutions with the same probability and a significance of 1.5 σ are found. The solutions for the Born cross section of ψ(3770) → p̄pπ0are 33.8 ± 1.8 ± 2.1 pb and (formula presented) pb (< 0.22 pb at a 90% confidence level). Using the estimated cross section and a constant decay amplitude approximation, the cross section σ(p̄p → ψ(3770)π0) is calculated for the kinematic situation of the planned P̄ANDA experiment. The maximum cross section corresponding to the two solutions is expected to be less than 0.79 nb at 90% confidence level and 122 ± 10 nb at a center-of-mass energy of 5.26 GeV.

Using 2917pb -1 of data accumulated at 3.773GeV, 44.5pb -1 of data accumulated at 3.65GeV and data accumulated during a ψ(3770) line-shape scan with the BESIII detector, the reaction e+e-→pp- is studied considering a possible interference between resonant and continuum amplitudes. The cross section of e+e-→ψ(3770)→pp-, σ(e+e-→ψ(3770)→pp-), is found to have two solutions, determined to be (0.059-0.020+0.070±0.012)pb with the phase angle φ=(255.8-26.6+39.0±4.8)° (

An energy scan near the τ pair production threshold has been performed using the BESIII detector. About 24 pb-1 of data, distributed over four scan points, were collected. This analysis is based on τ pair decays to ee, eμ, eh, μμ, μh, hh, eρ, μρ and πρ final states, where h denotes a charged π or K. The mass of the τ lepton is measured from a maximum likelihood fit to the τ pair production cross-section data to be mτ = (1776.91 ± 0.12-0.13+0.10) MeV=c2, which is currently the most precise value in a single measurement.

Using a sample of 1.3 × 10(9)  J/ψ events collected with the BESIII detector, we report the first observation of η(')→π(+)π(-)π(+)π(-) and η(')→π(+)π(-)π(0)π(0). The measured branching fractions are B(η(')→π(+)π(-)π(+)π(-)) = [8.53 ± 0.69(stat.) ± 0.64(syst.)]×10(-5) and B(η(')→π(+)π(-)π(0) π(0)) = [1.82 ± 0.35(stat.) ± 0.18(syst.)] × 10(-4), which are consistent with theoretical predictions based on a combination of chiral perturbation theory and vector-meson dominance.

By using a 2.92 fb-1 data sample taken at √s = 3.773 GeV with the BESIII detector operating at the BEPCII collider, we search for the radiative transitions ψ(3770) → γηc and γηc(2S) through the hadronic decays ηc(ηc (2S)) → K0SK±π+. No significant excess of signal events above background is observed. We set upper limits at a 90% confidence level for the product branching fractions to be B(ψ(3770) →γηc) ±B(ηc → K0SK±π+) < 1.6× 10-5 and B(ψ(3770) →γηc(2S)) ×B(ηc(2S) → K0SK+π+) 6.8 × 10-4 and B(ψ(3770) → γηc(2S)) < 2.0 × 10-3 at a 90% confidence level.

With 1.06 × 108 ψ(3686) events collected with the BESIII detector, the branching fraction of ψ (3686) → ωK+K- is measured to be (1.54 ± 0.04 ± 0.11) × 10-4. This is the most precise result to date, due to the largest ψ(3686) sample, improved signal reconstruction efficiency, good simulation of the detector performance, and a more accurate knowledge of the continuum contribution. Using the branching fraction of J/ψ → ωK+K-, the ratio β(ψ(3868) → ωK+K-)/β(J/ψ → ωK+K-) is determined to be (18.4 ± 3.7)%. This constitutes a significantly improved test of the 12% rule, with the uncertainty now dominated by the J/ψ branching fraction.

We study D0D̅0 pairs produced in e+e− collisions at √ s = 3.773 GeVusing a data sample of 2.92 fb−1 collected with the BESIII detector. We measuredthe asymmetry ACPKπ of the branching fractions of D → K−π+ in CP-odd and CP-even eigenstates to be (12.7 ± 1.3 ± 0.7) × 10−2. ACPKπ can be used to extract the strong phase difference δKπ between the doubly Cabibbo-suppressed process D̅0 → K−π+ and the Cabibbo-favored process D0 → K−π+. Using world-average values of external parameters, we obtain cos δKπ = 1.02 ±0.11 ±0.06 ±0.01. Here, the first and second uncertainties are statistical and systematic, respectively, while the third uncertainty arises from the external parameters. This is the most precise measurement of δKπ to date.

Based on a sample of (225.3 ± 2.8) × 106 J/ψ events collected with the BESIII detector, the electromagnetic Dalitz decays of J/ψ → Pe+e- (P = η'/η/π∗0) are studied. By reconstructing the pseudoscalar mesons in various decay modes, the decays J/ψ → η' e+e-, J/ψ → η e+e-, and J/ψ → π0 e+e- are observed for the first time. The branching fractions are determined to be B(J/ψ → η' e+e-) = (5.81 ± 0.16 ± 0.31) × 10-5, B(J/ψ → η e+e-) = (1.16 ± 0.07 ± 0.06) × 10-5, and B(J/ψ → π0 e+e-) = (7.56 ± 1.32 ±0.50) × 10-7, where the first errors are statistical and the second ones systematic.

We study the process e+ e- →(D* D*)± π∓ at a center-of-mass energy of 4.26 GeV using a 827  pb(-1) data sample obtained with the BESIII detector at the Beijing Electron Positron Collider. Based on a partial reconstruction technique, the Born cross section is measured to be (137±9±15)  pb. We observe a structure near the (D* D*)± threshold in the π∓ recoil mass spectrum, which we denote as the Zc±(4025). The measured mass and width of the structure are (4026.3±2.6±3.7)  MeV/c2 and (24.8±5.6±7.7)  MeV, respectively. Its production ratio σ(e+ e- → Zc±(4025)π∓ → (D* D*)± π∓)/σ(e+ e- → (D* D*)± π∓) is determined to be 0.65±0.09±0.06. The first uncertainties are statistical and the second are systematic.

Using (106.41 ± 0.86) × 106 ψ(3686) events collected with the BESIII detector at BEPCII, we study for the first time the decay χcJ → η'K+K- (J = 1, 2), where η' → γρ0 and η' → ηπ+π-. A partial wave analysis in the covariant tensor amplitude formalism is performed for the decay χc1 → η'K+K-. Intermediate processes χc1 → η' f0 (980), χc1 → η' f0 (1710), χc1 → η' f2' (1525) and χc1 → K∗0 (1430)± K∓ (K∗0 (1430)± → η' K±) are observed with statistical significances larger than 5σ, and their branching fractions are measured.

A search for the rare decays of J/ψ → Dsρ+ + c.c. and J/ψ → D0K∗0 + c.c. is performed with a data sample of 225.3-million J/ψ events collected with the Beijing Spectrometer III detector. No evident signal is observed. Upper limits on the branching fractions are determined to be B(J/ψ → Ds ρ+ + c.c.) < 1.3 × 10-5 and B(J/ψ → D0K ∗0+ c.c.) < 2.5 × 10-6 at the 90% confidence level.

We report a measurement of the branching fraction B(D+→μ+νμ)= [3.71±0.19(stat)±0.06(sys)]×10-4 based on 2.92fb-1 of data accumulated at s=3.773GeV with the BESIII detector at the BEPCII collider. This measurement, in conjunction with the Cabibbo-Kobayashi-Maskawa matrix element |Vcd| determined from a global Standard Model fit, implies a value for the weak decay constant fD+=(203.2±5.3±1.8)MeV. Additionally, using this branching fraction measurement together with a lattice QCD prediction for fD+, we find |Vcd|=0.2210±0.0058±0.0047. In either case, these are the most precise results for these quantities to date.

We perform an analysis of the D+→ K0Sπ+π0 Dalitz plot using a data set of 2.92 fb-1 of e+e- collisions at the ψ(3770) mass accumulated by the BESIII experiment, in which 166694 candidate events are selected with a background of 15.1%. The Dalitz plot is found to be well represented by a combination of six quasitwo- body decay channels [K0Sρ+, K0Sρ(1450)+, K∗0π+, K0 (1430)0π+, K (1680)0π+, κ0π+] plus a small nonresonant component. Using the fit fractions from this analysis, partial branching ratios are updated with higher precision than previous measurements.